LOXL2 and metastatic neoplasm: Baseline serum levels of LOXL2, a marker of collagen cross-linking, were higher in those patients with metastatic disease (p < 0.0001) or who were NED and being treated in the adjuvant setting (p = 0.04) compared with healthy controls.